发明名称 HUMAN ANTI-NGF NEUTRALIZING ANTIBODY AS SELECTIVE NGF PATHWAY INHIBITOR
摘要 <P>PROBLEM TO BE SOLVED: To provide a new, safe and effective method for treating pain by way of targeting a mediator or an exacerbator of pain of a low molecular weight such as NGF. <P>SOLUTION: Antibodies interact with or bind to a human nerve growth factor (NGF) and thereby neutralize the function of NGF, a pharmaceutical composition of the above antibodies, a method for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies, and a method of determining the amount of NGF in a sample using anti-NGF antibodies. <P>COPYRIGHT: (C)2010,JPO&INPIT
申请公布号 JP2010006812(A) 申请公布日期 2010.01.14
申请号 JP20090159335 申请日期 2009.07.03
申请人 AMGEN INC;MEDAREX INC 发明人 WILD KENNETH D;TREANOR JAMES J S;HUANG HAICHUN;INOUE HEATHER;ZHANG TIE J;MARTIN FRANK
分类号 C07K16/22;A61K39/395;A61P1/00;A61P1/04;A61P1/14;A61P1/18;A61P3/10;A61P9/10;A61P11/06;A61P13/10;A61P15/08;A61P17/02;A61P17/04;A61P17/06;A61P19/02;A61P25/06;A61P25/32;A61P27/02;A61P27/16;A61P29/00;A61P31/18;A61P35/00;A61P37/08;A61P39/02;A61P43/00;C12N1/15;C12N1/19;C12N1/21;C12N5/10;C12N15/02;C12N15/09;C12P21/08;G01N33/53 主分类号 C07K16/22
代理机构 代理人
主权项
地址